Please login to the form below

Not currently logged in
Email:
Password:

Cancer Drug Fund

This page shows the latest Cancer Drug Fund news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn on Opdivo for kidney cancer

NICE U-turn on Opdivo for kidney cancer

guidance. Opdivo (nivolumab) is now set to be recommended as a second-line treatment on the NHS in England and Wales almost immediately as the Cancer Drugs Fund will support the ... happy that NICE has made this recommendation for patients with advanced

Latest news

  • Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

    Reformed Cancer Drugs Fund backs its first drug - AZ’ s Tagrisso. ... AstraZeneca's Tagrisso (osimertinib) has become the first drug to be supported by the UK's newly-reformed Cancer Drugs Fund (CDF).

  • Pfizer warns against price-cutting after NICE backs Bosulif Pfizer warns against price-cutting after NICE backs Bosulif

    Pfizer warns against price-cutting after NICE backs Bosulif. Cancer drug is the first to be re-appraised form the CDF. ... NICE has approved the first re-appraised drug from the now-defunct Cancer Drugs Fund (CDF) - but Pfizer has warned that companies

  • Imbruvica wins wider European leukaemia licence Imbruvica wins wider European leukaemia licence

    AbbVie and Johnson &Johnson have been granted a European licence for the expanded use of their chemotherapy alternative drug Imbruvica. ... Despite Imbruvica's status as the most requested CLL drug available on the Cancer Drugs Fund (CDF), the

  • NICE changes tack on Sanofi's prostate cancer drug Jevtana NICE changes tack on Sanofi's prostate cancer drug Jevtana

    NICE changes tack on Sanofi's prostate cancer drug Jevtana. Approves the therapy for NHS use after accepting undisclosed additional discount. ... This important drug can offer precious extra time to men who are dealing with the latter stages of prostate

  • Roche faces Kadcyla pricing pressure in the UK Roche faces Kadcyla pricing pressure in the UK

    Roche faces Kadcyla pricing pressure in the UK. Leading breast cancer charity calls on firmto reduce the drug's cost. ... Breast Cancer Now has launched a petition - the second time pressure has been put on Roche recently over the cost of Kadcyla -

More from news
Approximately 1 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics